Novartis AG's marketing applications for skin cancer drugs Tafinlar and Mekinist were accepted by Chinese regulators, according to the country's Center for Drug Evaluation.
Tafinlar, also known as dabrafenib, inhibits a gene called BRAF, which can mutate and drive certain cancers. Mekinist, also known as trametinib, inhibits the MEK 1 and MEK 2 protein in cancer cells.
The U.S. Food and Drug Administration in 2013 approved Tafinlar and Mekinist as treatments for advanced melanoma, and later approved the drugs as a combination therapy for melanoma with BRAF V600E or V600K mutations, thyroid cancer and non-small cell lung cancer.
GlaxoSmithKline PLC developed Tafinlar and Mekinist, which were obtained by Novartis as part of its acquisition of GSK's oncology business in 2015.